AtheroNova Inc. is a clinical-stage biopharmaceutical company. The Company through its subsidiary, AtheroNova Operations, Inc., is focused on the research and development of compounds to regress atherosclerotic plaque and improve lipid profiles in humans. The Company develops various applications for its compounds to be used for the treatment of atherosclerosis. The Company's development products include AHRO-001 and AHRO-002. The Company's pipeline candidates include applications for the treatment of localized reduction of subcutaneous fat deposits through transdermal application, obesity, hypertension, diabetes and Peripheral Artery Disease (PAD). The Company's lead compound is AHRO-001. Through the process of reverse cholesterol transport, the compound is designed to dissolve plaque within the walls of the arteries and removes it from the body through natural metabolic processes. AHRO-001 and AHRO-002 are orally administered compounds.
ATHERONOVA INC. 
